. 2013 Jun 17;191(2):795–809. doi: 10.4049/jimmunol.1300778

Table I. rAgs of P. falciparum merozoites included in the study.

Ag	Gene ID	Region	Amino Acid Residues	Expression System	Outcome or Plasma Dilution
MSPs (GPI anchored)
MSP1-19^a	PFI1475w	MSP1-19	1597–1704	E. coli	1/1000
MSP1-42^a	PFI1475w	MSP1-42	1362–1720	E. coli	1/1000
MSP2^a	PFB0300c	Full length	19–249	E. coli	1/1000
MSP4^a	PFB0310c	Full length	21–248	E. coli	1/1000
MSP10^a	PFF0995c	Full ectodomain	29–506	WGCF	1/1000
Pf12^a	PFF0615c	Full ectodomain	25–321	E. coli	1/1000
Pf12p	PFF0620c	Full ectodomain	21–352	E. coli	Poor coating
Pf38^a	PFE0395c	Full ectodomain	22–327	E. coli	1/1000
Pf92	PF13-0338	Full ectodomain	28–772	WGCF	Poor coating
MSPs (non-GPI anchored)
MSP3^a	PF10-0345	Full ectodomain	27–354	WGCF	1/1000
MSP3^a	PF10-0345	Long synthetic peptide	154–249	Peptide	1/250
MSP6^a	PF10-0346	Full ectodomain	23–371	WGCF	1/1000
MSP7^a	PF13-0197	Full ectodomain	24–351	WGCF	1/1000
MSRP1^a	PF13-0196	Full ectodomain	23–380	WGCF	1/500
MSRP2	MAL13P1.174	Full ectodomain	23–281	WGCF	Poor immunoreactivity
ABRA/MSP9^a	PFK1385c	Full ectodomain	25–743	WGCF	1/250
H101	PF10-0347	Full ectodomain	25–424	WGCF	Poor immunoreactivity
H103/MSP11^a	PF10-0352	Full ectodomain	26–405	WGCF	1/250
GLURP^a	PF10-0344	R2 peptide	887–905	Peptide	1/1000
S-Ag	PF10-0343	Full ectodomain	25–585	WGCF	Poor coating
S-Ag	PF10-0343	Repeat sequence	136–151	Peptide	Poor coating
SERA4	PFB0345c	Papain domain	376–962	WGCF	Poor expression
SERA5^a	PFB0340c	Central domain	391–828	E. coli	1/500
SERA5	PFB0340c	Papain domain	513–822	WGCF	Poor expression
Pf41^a	PFD0240c	Full ectodomain	21–378	E. coli	1/1000
MSPDBL1^a^,^b	PF10-0348	Full ectodomain	26–697	WGCF	1/500
MSPDBL1 (PfMSPDBL1)^b	PF10-0348	DBL domain	243–443	E. coli	Poor coating
MSPDBL2^a^,^c	PF10-0355	Full ectodomain	30–762	WGCF	1/500
MSP3.4	PF10-0350	Full ectodomain	23–712	WGCF	Poor immunoreactivity
ROM4	PFE0340c	Full ectodomain	17–759	WGCF	Poor immunoreactivity
Microneme Ags
AMA1^a	PF11-0344	Full ectodomain	26–546	WGCF	1/1000
EBA140RII^a	MAL13P1.60	Region II	146-713	Pichia	1/500
EBA140RIII-V^a	MAL13P1.60	Region III–V	746–1045	E. coli	1/500
EBA175F2^a	PF07-0128	F2	447–795	E. coli	1/500
EBA175RII^a	PF07-0128	Region II	145–760	Pichia	1/1000
EBA175RIII-V^a	PF07-0128	Region III–V	761–1271	E. coli	1/500
EBA181RII	PFA0125c	Region II	122–704	WGCF	Poor expression
EBA181RIII-V^a	PFA0125c	Region III–V	755–1339	E. coli	1/500
MTRAP	PF10-0281	Full ectodomain	24–432	WGCF	Poor immunoreactivity
ASP	PFD0295c	Full ectodomain	22–711	WGCF	Poor coating
GAMA^a	PF08-0008	Full ectodomain	25–714	WGCF	1/250
GAMA^a	PF08-0008	N-terminal	25–337	WGCF	1/500
GAMA^a	PF08-0008	C-terminal	500–714	WGCF	1/500
Ripr^a	PFC1045c	EGF-like domain	279–995	WGCF	1/500
Ripr	PFC1045c	N-terminal	238–368	WGCF	Poor expression
Ripr	PFC1045c	C-terminal	791–900	WGCF	Poor expression
SUB2^a	PF11-0381	N-terminal	19–681	WGCF	1/500
SUB2	PF11-0381	C-terminal	625–1136	WGCF	Poor coating
Rhoptry proteins
RAMA^a	MAL7P1.208	Full ectodomain	18–786	WGCF	1/250
PfRh1	PFD0110w	N-terminal	500–833	WGCF	Poor expression
PfRh2-297^a	PF13-0198	PfRh2-297	297–726	E. coli	1/500
PfRh2-2030^a	PF13-0198	PfRh2-2030	2030–2528	E. coli	1/500
PfRh2a^a	PF13-0198	PfRh2a-2874	2874–3060	E. coli	1/500
PfRh2b^a	PF13-0198	PfRh2b-2792	2792–3185	E. coli	1/500
PfRh4.1	PFD1150c	PfRh4.1	607–773	E. coli	Poor expression
PfRh4.2^a	PFD1150c	PfRh4.2	1277–1451	E. coli	1/1000
PfRh4.4	PFD1150c	PfRh4.4	1445–1619	E. coli	Poor expression
PfRh4.9^a	PFD1150c	PfRh4.9	28–340	E. coli	1/500
PfRh5^a	PFD1145c	Full ectodomain	25–526	WGCF	1/500
RALP-1^a	MAL7P1.119	Full ectodomain	21–749	WGCF	1/500
Rhop148	PF13-0348	N-terminal	1–694	WGCF	Poor expression
Rhop148	PF13-0348	C-terminal	569–1262	WGCF	Poor expression
RhopH1(9)	PFI1730w	N-terminal	267–850	WGCF	Poor expression
RhopH1(9)	PFI1730w	C-terminal	752–1340	WGCF	Poor expression
RhopH1(3.1)^a	PFC0120w	N-terminal	25–721	WGCF	1/500
RhopH1(3.1)	PFC0120w	C-terminal	722–1417	WGCF	Poor coating
RhopH1(3.2)	PFC0110w	N-terminal	25–722	WGCF	Poor immunoreactivity
RhopH1(3.2)	PFC0110w	C-terminal	723–1416	WGCF	Poor expression
RhopH1(2)^a	PFB0935w	N-terminal	25–732	WGCF	1/500
RhopH1(2)	PFB0935w	C-terminal	733–1440	WGCF	Poor coating
RhopH2	PFI1445w	N-terminal	20–693	WGCF	Poor coating
RhopH2	PFI1445w	C-terminal	94–1378	WGCF	Poor coating
RhopH3	PFI0265c	C-terminal	56–897	WGCF	Poor coating
RON2^a	PF14-0495	N-terminal	84–968	WGCF	1/500
RON2	PF14-0495	C-terminal	1786–2071	WGCF	Poor coating
RON3	PFL2505c	N-terminal	574–1394	WGCF	Poor expression
RON3	PFL2505c	C-terminal	1395–2215	WGCF	Poor expression
RON4^a	PF11-0168	N-terminal	25–709	WGCF	1/500
RON4	PF11-0168	C-terminal	710–1201	WGCF	Poor expression
RON6^a	PFB0680w	C-terminal	124–950	WGCF	1/500
SPATR	PFB0570w	Full ectodomain	23–250	WGCF	Poor coating
Pf34	PFD0955w	Full ectodomain	26–299	WGCF	Poor immunoreactivity
Likely apical proteins without clearly defined localization
Pf113^a	PF14-0201	C-terminal	97–948	WGCF	1/500
HYP	PF10-0119	Full ectodomain	22–267	WGCF	Poor immunoreactivity
HYP	PFL0300c	Full ectodomain	24–304	WGCF	Poor immunoreactivity
HYP	Pf10-0166	Full ectodomain	26–310	WGCF	Poor coating
HYP	PF14-0119	Full ectodomain	22–320	WGCF	Poor immunoreactivity
PTRAMP	PFL0870w	Full ectodomain	26–309	WGCF	Poor immunoreactivity
HYP	PFD1130w	Full ectodomain	27–362	WGCF	Poor immunoreactivity
HYP	PFB0475c	Full ectodomain	33–446	WGCF	Poor immunoreactivity
Protease	PFD0230c	Papain domain	116–939	WGCF	Poor expression
Nonmerozoite Ags
CSP^a	PFC0210c	Repeat region	(NANP)₆	Peptide	1/125

Bioinformatics approaches were used to identify merozoite Ags that were potential targets of protective Ab responses. All Ags listed demonstrated peak expression during late trophozoite/schizont stage, and all were predicted to have a signal peptide (except Rhop148). Selection was also made on the likely accessibility to Ab recognition (i.e., merozoite surface or invasion organelles). Ags predicted to have a GPI anchor (as listed) are likely to be localized to the merozoite surface. The localization of some Ags is still not well established. Known localization for all Ags was assessed using the ApiLoc database and used to categorize the Ags in the respective areas in the table. Homology to known merozoite Ags was also assessed using the PlasmoDB database. Ag expression was in E. coli, P. pastoris, or the WGCF system. Peptides were synthesized commercially.

^{^a}

These Ags were tested in the prospective cohort of PNG children at the plasma dilution indicated. Ags were not tested in the cohort if they were poorly expressed or yielded poor results in screening ELISAs (poor Ag coating or poor immunoreactivity when tested with malaria-exposed adult controls).

^{^b}

This protein has recently been renamed DBLMSP.

^{^c}

This protein has recently been renamed MSP3.8.

S-Ag repeat sequence peptide: KVSNGGEDEVSNGRED.

HYP, Hypothetical protein.